- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Fixed-dose Combination Agent Approved to Treat Elevated LDL Cholesterol
Ezetimibe/simvastatin (Vytorin)recently became available for thetreatment of high LDL cholesterollevels, as adjunctive therapy to dietarymodification, in patients withprimary hypercholesterolemia ormixed hyperlipidemia. This drug,from Merck/Schering-Plough Pharmaceuticals,inhibits the productionof cholesterol in the liver and blocksthe absorption of cholesterol in theGI tract, including cholesterol obtainedfrom food.
New Agent forCholesterol Reduction
Ezetimibe/simvastatin (Vytorin)recently became available for thetreatment of high LDL cholesterollevels, as adjunctive therapy to dietarymodification, in patients withprimary hypercholesterolemia ormixed hyperlipidemia. This drug,from Merck/Schering-Plough Pharmaceuticals,inhibits the productionof cholesterol in the liver and blocksthe absorption of cholesterol in theGI tract, including cholesterol obtainedfrom food.
The recommended startingdosage is 10 mg ezetimibe/20 mgsimvastatin once a day. Limit themaximum dosage to 10/10 mg dailyfor patients taking cyclosporine and10/20 mg daily for patients takingamiodarone or verapamil.
The most common side effectsare headache, upper respiratorytract infection, myalgia, influenza,and extremity pain. Advise patientsto report muscle pain, tenderness, orweakness to a health care providerpromptly. This agent should be discontinuedif myopathy is reported.
